Patent Filed for Novel Depression Therapy by Clearmind Medicine, NeuroThera Labs
Summary
Clearmind Medicine Inc., in collaboration with NeuroThera Labs, has filed a patent application in Hong Kong for an innovative combination therapy targeting major depressive disorder (MDD). This therapy combines Clearmind's proprietary MEAI with Palmitoylethanolamide (PEA) sourced by NeuroThera. This development follows a recent announcement on March 10, 2026, regarding the publication of an international patent application for a novel combination therapy, with this news providing specific details on the indication and collaboration. For a micro-cap biotech company, securing intellectual property for a potential treatment for a widespread condition like MDD is a significant positive step, enhancing its pipeline value and long-term prospects. Investors will be watching for further updates on the patent's approval and the progression of this specific combination therapy into clinical trials.
At the time of this announcement, CMND was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.75 to $52.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: The newswire.ca.